Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults

Jeff M. Turner, Jason B. Kaplan, Hillel W. Cohen, Henny H. Billett

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: There are scant data regarding the relative efficacy of exchange transfusion (XC) versus simple transfusion (ST) for treatment of sickle cell anemia acute chest syndrome (ACS). Study Design and Methods: Twenty patients who received XC for ACS were compared with 20 ST patients. Hemoglobin (Hb) levels, platelet and white blood cell counts, lactate dehydrogenase (LDH), indirect bilirubin, and temperature were used to assess disease severity. Primary outcome was postprocedure length of hospital stay; secondary outcome was total length of stay. Results: Cohorts were similar with regard to age; sex; prior ACS episodes; echocardiogram results; and antibiotic, bronchodilator, and hydroxyurea use. Maximum temperature recorded was higher in the XC group (39.1°C vs. 38.4°C, p = 0.02), but LDH, WBCs, and indirect bilirubin were comparable. Admission Hb levels were higher for XC (XC 8.6 g/dL vs. ST 7.4 g/dL, p = 0.02) and XC had higher peak Hb levels during hospitalization (10.4 ± 1.4 g/dL vs. 9.3 ± 1.0 g/dL, p ≤ 0.01). No differences were demonstrable in postprocedure length of stay (XC 5.6 days vs. ST 5.9 days, p = 0.82) or total length of stay (XC 8.4 days vs. ST 8.0 days, p = 0.76). A total of 10.3 ± 3.0 units were transfused for XC compared to 2.4 ± 1.2 units for ST (p < 0.001). CONCLUSIONS: Based on postprocedure length of stay or total length of stay, we could not detect a difference in the efficacy of XC compared to ST in populations despite red blood cell product usage fourfold higher in the XC group. We suggest that it is time for an adequately powered, randomized trial to examine the true risk:benefit ratio of XC in ACS.

Original languageEnglish (US)
Pages (from-to)863-868
Number of pages6
JournalTransfusion
Volume49
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Acute Chest Syndrome
Sickle Cell Anemia
Length of Stay
Hemoglobins
L-Lactate Dehydrogenase
Bilirubin
Temperature
Hydroxyurea
Bronchodilator Agents
Leukocyte Count
Hospitalization
Blood Platelets
Erythrocytes
Odds Ratio
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults. / Turner, Jeff M.; Kaplan, Jason B.; Cohen, Hillel W.; Billett, Henny H.

In: Transfusion, Vol. 49, No. 5, 05.2009, p. 863-868.

Research output: Contribution to journalArticle

Turner, Jeff M. ; Kaplan, Jason B. ; Cohen, Hillel W. ; Billett, Henny H. / Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults. In: Transfusion. 2009 ; Vol. 49, No. 5. pp. 863-868.
@article{8b866dad0eab47b5a1f90c6785a3fd4e,
title = "Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults",
abstract = "Background: There are scant data regarding the relative efficacy of exchange transfusion (XC) versus simple transfusion (ST) for treatment of sickle cell anemia acute chest syndrome (ACS). Study Design and Methods: Twenty patients who received XC for ACS were compared with 20 ST patients. Hemoglobin (Hb) levels, platelet and white blood cell counts, lactate dehydrogenase (LDH), indirect bilirubin, and temperature were used to assess disease severity. Primary outcome was postprocedure length of hospital stay; secondary outcome was total length of stay. Results: Cohorts were similar with regard to age; sex; prior ACS episodes; echocardiogram results; and antibiotic, bronchodilator, and hydroxyurea use. Maximum temperature recorded was higher in the XC group (39.1°C vs. 38.4°C, p = 0.02), but LDH, WBCs, and indirect bilirubin were comparable. Admission Hb levels were higher for XC (XC 8.6 g/dL vs. ST 7.4 g/dL, p = 0.02) and XC had higher peak Hb levels during hospitalization (10.4 ± 1.4 g/dL vs. 9.3 ± 1.0 g/dL, p ≤ 0.01). No differences were demonstrable in postprocedure length of stay (XC 5.6 days vs. ST 5.9 days, p = 0.82) or total length of stay (XC 8.4 days vs. ST 8.0 days, p = 0.76). A total of 10.3 ± 3.0 units were transfused for XC compared to 2.4 ± 1.2 units for ST (p < 0.001). CONCLUSIONS: Based on postprocedure length of stay or total length of stay, we could not detect a difference in the efficacy of XC compared to ST in populations despite red blood cell product usage fourfold higher in the XC group. We suggest that it is time for an adequately powered, randomized trial to examine the true risk:benefit ratio of XC in ACS.",
author = "Turner, {Jeff M.} and Kaplan, {Jason B.} and Cohen, {Hillel W.} and Billett, {Henny H.}",
year = "2009",
month = "5",
doi = "10.1111/j.1537-2995.2008.02075.x",
language = "English (US)",
volume = "49",
pages = "863--868",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults

AU - Turner, Jeff M.

AU - Kaplan, Jason B.

AU - Cohen, Hillel W.

AU - Billett, Henny H.

PY - 2009/5

Y1 - 2009/5

N2 - Background: There are scant data regarding the relative efficacy of exchange transfusion (XC) versus simple transfusion (ST) for treatment of sickle cell anemia acute chest syndrome (ACS). Study Design and Methods: Twenty patients who received XC for ACS were compared with 20 ST patients. Hemoglobin (Hb) levels, platelet and white blood cell counts, lactate dehydrogenase (LDH), indirect bilirubin, and temperature were used to assess disease severity. Primary outcome was postprocedure length of hospital stay; secondary outcome was total length of stay. Results: Cohorts were similar with regard to age; sex; prior ACS episodes; echocardiogram results; and antibiotic, bronchodilator, and hydroxyurea use. Maximum temperature recorded was higher in the XC group (39.1°C vs. 38.4°C, p = 0.02), but LDH, WBCs, and indirect bilirubin were comparable. Admission Hb levels were higher for XC (XC 8.6 g/dL vs. ST 7.4 g/dL, p = 0.02) and XC had higher peak Hb levels during hospitalization (10.4 ± 1.4 g/dL vs. 9.3 ± 1.0 g/dL, p ≤ 0.01). No differences were demonstrable in postprocedure length of stay (XC 5.6 days vs. ST 5.9 days, p = 0.82) or total length of stay (XC 8.4 days vs. ST 8.0 days, p = 0.76). A total of 10.3 ± 3.0 units were transfused for XC compared to 2.4 ± 1.2 units for ST (p < 0.001). CONCLUSIONS: Based on postprocedure length of stay or total length of stay, we could not detect a difference in the efficacy of XC compared to ST in populations despite red blood cell product usage fourfold higher in the XC group. We suggest that it is time for an adequately powered, randomized trial to examine the true risk:benefit ratio of XC in ACS.

AB - Background: There are scant data regarding the relative efficacy of exchange transfusion (XC) versus simple transfusion (ST) for treatment of sickle cell anemia acute chest syndrome (ACS). Study Design and Methods: Twenty patients who received XC for ACS were compared with 20 ST patients. Hemoglobin (Hb) levels, platelet and white blood cell counts, lactate dehydrogenase (LDH), indirect bilirubin, and temperature were used to assess disease severity. Primary outcome was postprocedure length of hospital stay; secondary outcome was total length of stay. Results: Cohorts were similar with regard to age; sex; prior ACS episodes; echocardiogram results; and antibiotic, bronchodilator, and hydroxyurea use. Maximum temperature recorded was higher in the XC group (39.1°C vs. 38.4°C, p = 0.02), but LDH, WBCs, and indirect bilirubin were comparable. Admission Hb levels were higher for XC (XC 8.6 g/dL vs. ST 7.4 g/dL, p = 0.02) and XC had higher peak Hb levels during hospitalization (10.4 ± 1.4 g/dL vs. 9.3 ± 1.0 g/dL, p ≤ 0.01). No differences were demonstrable in postprocedure length of stay (XC 5.6 days vs. ST 5.9 days, p = 0.82) or total length of stay (XC 8.4 days vs. ST 8.0 days, p = 0.76). A total of 10.3 ± 3.0 units were transfused for XC compared to 2.4 ± 1.2 units for ST (p < 0.001). CONCLUSIONS: Based on postprocedure length of stay or total length of stay, we could not detect a difference in the efficacy of XC compared to ST in populations despite red blood cell product usage fourfold higher in the XC group. We suggest that it is time for an adequately powered, randomized trial to examine the true risk:benefit ratio of XC in ACS.

UR - http://www.scopus.com/inward/record.url?scp=65349181445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349181445&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2008.02075.x

DO - 10.1111/j.1537-2995.2008.02075.x

M3 - Article

C2 - 19309475

AN - SCOPUS:65349181445

VL - 49

SP - 863

EP - 868

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 5

ER -